By Stephen Nakrosis

The Janssen Pharmaceutical Companies of Johnson & Johnson on Tuesday said the U.S. Food and Drug Administration had granted Breakthrough Therapy Designation for JNJ-61186372 to treat certain patients with small cell lung cancer.

The company said the treatment was for "patients with metastatic non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy."

Janssen said the FDA's decision was supported by a Phase 1 study and that enrollment into the Part 2 dose expansion cohorts is ongoing.

-Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

March 10, 2020 16:42 ET (20:42 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson